Lunit (KRX:328130) develops Lunit INSIGHT (radiology AI) and Lunit SCOPE (oncology biomarkers). Cleared in 60+ countries. Used by 3,000+ hospitals. Founded by Anthony Paek. IPO'd 2022. Seoul HQ.
Builder’s Brief
Lunit is a healthcare tool on Falcoscan. AI for medical imaging. Falcoscan rates Lunit with an Opportunity score of 75/100, a Saturation score of 18/100, and a Wrapper-risk score of 5/100. Market signal: rising. Lunit is founded in 2013, currently at Public stage. Pricing: Paid.
Market position · Healthcare
How Lunit compares in Healthcare
Lunit's opportunity score of 75 ranks #123 of 137 live Healthcare tools on Falcoscan, 6.8 points below the category average of 81.8. Its saturation score is 18/100, against a category average of 11. 75 of the 137 live Healthcare tools carry a hot signal, and Falcoscan has recorded 8 shutdowns in the category.
The top-rated live Healthcare tools on Falcoscan, other than Lunit, are DeepMind AlphaFold, Nuance DAX Copilot, Viz.ai AI Stroke Response, Tempus AI Diagnostics, and Viz.ai Stroke AI.
Is Lunit still operating?
Yes. Falcoscan's operating checks list Lunit as active.
Where is Lunit based?
Lunit is headquartered in Seoul, South Korea.
Does Lunit have an API?
Falcoscan's records show no public API for Lunit.
Who is Lunit for?
Lunit is built for enterprises, hospitals, and healthcare providers.